US Patent

US8168793 — Nitrocatechol derivatives as COMT inhibitors

Method of Use · Assigned to Bial Portela and Cia SA · Expires 2029-04-02 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new compounds with potentially valuable pharmaceutical properties as inhibitors of catechol-O-methyltransferase (COMT).

USPTO Abstract

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3869`	—
`U-3869`	—

Patent Metadata

Patent number: US8168793
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.